Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 Press Release dated May 1, 2019.
ALNYLAM PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a51977503_ex991.htm EXHIBIT 99.1 Exhibit 99.1 Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity − Achieved First Quarter 2019 ONPATTRO® Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide – − Achieved Positive Results in ENVISION Phase 3 Study of Givosiran – − Formed Broad Collaboration with Regeneron to Discover,…
To view the full exhibit click here
About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.
